Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;38(12):e70035.
doi: 10.1111/ctr.70035.

Outcomes of Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: How Do Anti-HLA Antibodies Impact?: The Impact of Anti-HLA Antibodies on Transplantation Outcomes in Thalassemia Major

Gizem Zengin Ersoy  1 , Basak Adakli Aksoy  1 , Melek Erdem  2 , Lokman Karataş  3 , Selime Aydoğdu  4 , Özlem Başoğlu Öner  1 , Gürcan Dikme  5 , Ceyhun Bozkurt  2 , Tunç Fışgın  1
Affiliations

Outcomes of Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: How Do Anti-HLA Antibodies Impact?: The Impact of Anti-HLA Antibodies on Transplantation Outcomes in Thalassemia Major

Gizem Zengin Ersoy et al. Clin Transplant. 2024 Dec.

Abstract

Aim: To investigate the effects of anti-human Leucocyte Antigen (HLA) antibody positivity on early hematopoietic stem cell transplantation (HSCT) results in patients with thalassemia major (TM).

Methods: One hundred and twenty-four HLA-matched HSCTs were performed in patients with TM between 2015 and 2022. Ninety-one patients were screened for anti-HLA antibodies by testing panel reactive antigens (PRA). Demographic and transplantation characteristics of patients were recorded. The presence of PRA was tested with the Antibody Testing Assay (Luminex LIFECODES HLA Antibody Identification System).

Results: The number of PRA-positive patients was 54. There was no relationship between acute graft versus host disease (GVHD), chronic GVHD, grade of GVHD, and viral reactivation of the patients. However, platelet engraftment took around 3 days longer in the PRA-positive group (p = 0.05). The median number of erythrocyte transfusions was significantly higher in PRA-positive patients in the post-transplant period (p = 0.003), as was the median number of platelet transfusions (p = 0.003). Treosulfan conditioning increased the stable mixed chimerism (MC) rate by 3.8-fold (p = 0.011). In contrast, reduced rates of MC were found in patients who received matched unrelated donor cells or peripherally derived stem cells (p = 0.011 and p = 0.039, respectively) in the posttransplantation period in TM patients. PRA-positivity did not affect MC (p = 0.478). However, 80% of patients who had primary graft failure (n = 5; p = 0.59) and 75% of patients who died (n = 4) were PRA positive (p = 0.64), but these results were statistically insignificant due to the low number of patients.

Conclusion: Anti-HLA antibodies primarily delayed platelet engraftment in TM patients and increased the erythrocyte and thrombocyte transfusion requirements. Although PRA positivity was more common in patients with primary graft failure or who died, there was no statistically significant impact of PRA positivity on chimerism, acute or chronic GVHD, viral activation, or mortality rates.

Keywords: anti‐HLA antibodies; panel reactive antigens; thalassemia major; transplantation.

PubMed Disclaimer

References

    1. J. M. Tiercy and F. Claas, “Impact of HLA Diversity On Donor Selection in Organ and Stem Cell Transplantation,” Human Heredity 76 (2014): 178–186.
    1. P. Cruz‐Tapias, J. Castiblanco, and J.‐M Anaya, Major Histocompatibility Complex: Antigen Processing and Presentation. 2013, https://www.ncbi.nlm.nih.gov/books/NBK459467/.
    1. F. Kissmeyer‐Nielsen, S. Olsen, V. P. Petersen, et al., “Hyperacute Rejection of Kidney Allografts, Associated With Pre‐Existing Humoral Antibodies Against Donor Cells,” Lancet [Internet] 2 (1966): 662–665.
    1. E. Hod and J. Schwartz, “Platelet Transfusion Refractoriness,” British Journal of Haematology 142 (2008): 348–360.
    1. U. La Rocca, M. P. Perrone, A. Piciocchi, et al., “Anti‐HLA Donor‐Specific Antibodies in Allogeneic Stem Cell Transplantation: Management and Desensitization Protocol,” Bone Marrow Transplantation 54 (2019): 1717–1720.

MeSH terms

LinkOut - more resources